What is Anavex Life Sciences's earnings per share (EPS)?

Anavex Life Sciences (AVXL) reported diluted earnings per share of -$0.54 for fiscal year 2025. This represents a -3.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Anavex Life Sciences (AVXL) Financials

AVXL

FY2025 annual

Revenue Not reported for FY2025

Net Income -$46.4M -7.8% YoY

EPS (Diluted) -$0.54 -3.8% YoY

Operating Cash Flow -$39.0M -26.7% YoY

Market Cap $242.9M as of Sep 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.2x on $112.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Aug 28, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q3 FY2026, filed Aug 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVXL SEC filings page.

This page shows Anavex Life Sciences (AVXL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVXL FY2025 2026-08-28

Anavex's dominant mechanic is R&D-funded development: persistent operating losses consume assets while equity financing supports the balance sheet.

In FY2025, operating cash flow of -$39.0M remained close to net loss of -$46.4M; both worsened from FY2024, so the reported loss tracks cash consumption rather than being mostly an accrual effect. This cash-to-earnings alignment indicates that operating performance is consuming resources directly, not merely reflecting non-cash accounting charges.

The balance sheet is lightly debt-funded: FY2025 liabilities were $8.9M against total equity of $94.9M, with debt-to-equity at 0.1x. Yet total assets fell from $161.6M in FY2021 to $103.8M in FY2025, showing that operating losses have reduced the asset cushion without a corresponding build-up of borrowing.

R&D remained the core spending engine at $37.6M versus SG&A of $13.8M in FY2025, so the cost base is concentrated in development work rather than commercial overhead. Shares outstanding rose from 76.0M in FY2021 to 89.3M in FY2025, while FY2025 financing cash flow was $9.4M; this points to equity-funded operations, with the latest financing inflow smaller than the year's operating cash outflow. The reported cash-and-investment balance equaled 31.5 months of the latest annual operating outflow at FY2025, a liquidity snapshot rather than evidence of operating self-funding.

Financial Health Signals

Financial health score not available

Anavex Life Sciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/5

Anavex Life Sciences passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Anavex Life Sciences reported a net loss of $46.4M while operations used $39.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Anavex Life Sciences reported an operating loss of $51.4M against $4.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

$7.8M

YoY+159.1%

QoQ+246.6%

Anavex Life Sciences reported $7.8M in net income in Q3 2026. This represents an increase of 159.1% from the same quarter a year earlier. Against the prior quarter it is up 246.6%.

EPS (Diluted)

$0.08

YoY+150.0%

QoQ+233.3%

Anavex Life Sciences earned $0.08 per diluted share (EPS) in Q3 2026. This represents an increase of 150.0% from the same quarter a year earlier. Against the prior quarter it is up 233.3%.

Revenue

Not reported for Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$118.3M

YoY+17.0%

QoQ-7.1%

5Y CAGR-5.6%

10Y CAGR+28.4%

Anavex Life Sciences held $118.3M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

93M

YoY+7.9%

QoQ0.0%

5Y CAGR+4.1%

10Y CAGR+10.0%

Anavex Life Sciences had 93M shares outstanding in Q3 2026. This represents an increase of 7.9% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

7.0%

YoY+21.5pp

QoQ+11.3pp

Anavex Life Sciences's ROE was 7.0% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 21.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

None of these metrics is reported for Q3 2026.

AVXL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVXL quarterly income statement

Metric	TTM	FY2510-K/A	FY2410-K/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
R&D Expenses	N/A	$37.6M-10.1%	$41.8M-4.3%	$43.7M+15.3%	$37.9M+15.0%	$33.0M+30.7%	$25.2M+13.3%	$22.3M+66.8%	$13.3M+25.0%	$10.7M+47.1%	$7.3M+219.3%	$2.3M+210.2%	$732K+177.6%	$264K	N/A	N/A
SG&A Expenses	N/A	$13.8M+25.2%	$11.0M-8.4%	$12.0M-7.8%	$13.1M+44.9%	$9.0M+54.0%	$5.9M-14.5%	$6.8M+14.3%	$6.0M+19.6%	$5.0M-39.9%	$8.3M+72.3%	$4.8M+116.3%	$2.2M	$0	$0	$0
Operating Income	N/A	-$51.4M+2.8%	-$52.9M+5.2%	-$55.8M-9.4%	-$51.0M-21.4%	-$42.0M-35.1%	-$31.1M	N/A	N/A	N/A	N/A	N/A	-$3.0M	N/A	N/A	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3.0M	N/A	N/A	N/A
Interest Expense	N/A	$4.7M-36.1%	$7.3M+12.3%	$6.5M+588.4%	$947K+3542.3%	$26K-85.6%	$180K-13.2%	$207K-18.7%	$255K+189.6%	$88K+678.1%	$11K-84.2%	$72K+913.2%	$7K-86.2%	$51K	N/A	$90K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.4M	N/A	N/A	N/A
Net Income	N/A	-$46.4M-7.8%	-$43.0M+9.5%	-$47.5M+1.0%	-$48.0M-26.6%	-$37.9M-44.2%	-$26.3M+0.1%	-$26.3M-52.4%	-$17.3M-28.2%	-$13.5M+8.7%	-$14.7M-21.7%	-$12.1M-21.5%	-$10.0M	N/A	N/A	N/A
EPS (Basic)	N/A	-$0.54-3.8%	-$0.52+13.3%	-$0.60+3.2%	-$0.62-14.8%	-$0.54	N/A	N/A	N/A	N/A	-$0.42+35.4%	-$0.65+36.3%	-$1.02-750.0%	-$0.12	N/A	N/A
EPS (Diluted)	-$0.15	-$0.54-3.8%	-$0.52+13.3%	-$0.60+3.2%	-$0.62-14.8%	-$0.54	N/A	N/A	N/A	N/A	-$0.42	-$0.65	-$1.02-750.0%	-$0.12+58.6%	-$0.290.0%	-$0.29
Diluted Shares (Avg)	N/A	85M+2.2%	83M+4.6%	80M+3.7%	77M+10.2%	70M	N/A	N/A	N/A	N/A	35M	19M	10M-69.3%	32M+13.3%	28M+11.9%	25M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A
R&D Expenses	N/A	$4.2M-57.6%	$4.7M-55.4%	N/A	$10.0M-15.7%	$9.9M+1.7%	$10.4M+20.3%	N/A
SG&A Expenses	$2.0M-54.8%	$2.3M-12.6%	$2.1M-32.4%	N/A	$4.5M+61.2%	$2.6M-9.5%	$3.1M+16.8%	N/A
Operating Income	$6.7M+146.6%	-$6.5M+48.2%	-$6.8M+50.1%	N/A	-$14.5M+1.0%	-$12.5M+0.9%	-$13.6M-19.5%	N/A
Interest Expense	$1.1M-0.3%	$1.1M-12.3%	$1.1M-22.6%	N/A	$1.1M-40.1%	$1.2M-31.1%	$1.4M-30.6%	N/A
Income Tax	N/A	N/A	$18K	N/A	N/A	N/A	N/A	N/A
Net Income	$7.8M+159.1%	-$5.3M+52.3%	-$5.7M+53.1%	N/A	-$13.2M-8.4%	-$11.2M-6.2%	-$12.1M-40.5%	N/A
EPS (Basic)	$0.08+150.0%	-$0.06+53.8%	-$0.06+57.1%	-$0.11+21.4%	-$0.16-14.3%	-$0.130.0%	-$0.14-27.3%	-$0.14-7.7%
EPS (Diluted)	$0.08+150.0%	-$0.06+53.8%	-$0.06+57.1%	-$0.11+21.4%	-$0.16-14.3%	-$0.130.0%	-$0.14-27.3%	-$0.14-7.7%
Diluted Shares (Avg)	92.90B+8.8%	93M+8.9%	89M+5.0%	N/A	85.38B+100899.9%	85M+3.2%	85M+3.3%	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA.

AVXL Balance Sheet

AVXL quarterly balance sheet

Metric	FY2510-K/A	FY2410-K/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$103.8M-23.4%	$135.6M-12.2%	$154.4M+1.1%	$152.7M-5.5%	$161.6M+367.9%	$34.5M+36.4%	$25.3M-3.3%	$26.2M-5.9%	$27.8M+193.1%	$9.5M-38.6%	$15.5M+110.4%	$7.4M+1769.0%	$393K+2891.3%	$13K-93.5%	$203K
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	$25.3M-2.8%	$26.1M-6.2%	$27.8M+194.1%	$9.4M-38.9%	$15.5M+110.4%	$7.4M+1768.4%	$393K+3028.3%	$13K-93.7%	$201K
Cash & Equivalents	$102.6M-22.4%	$132.2M-12.5%	$151.0M+1.3%	$149.2M-1.9%	$152.1M+420.0%	$29.2M+31.8%	$22.2M-3.2%	$22.9M-16.4%	$27.4M+198.7%	$9.2M-39.9%	$15.3M+110.6%	$7.3M+2004.5%	$345K+2937.1%	$11K-91.6%	$135K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$8.9M-41.5%	$15.3M+22.1%	$12.5M+22.7%	$10.2M-5.4%	$10.8M+47.8%	$7.3M+45.0%	$5.0M+29.7%	$3.9M+8.4%	$3.6M+12.3%	$3.2M+19.9%	$2.7M-62.8%	$7.2M+150.7%	$2.9M-1.1%	$2.9M+114.7%	$1.3M
Current Liabilities	N/A	N/A	N/A	N/A	$10.8M+47.8%	$7.3M+45.0%	$5.0M+29.7%	$3.9M+8.4%	$3.6M+12.3%	$3.2M+19.9%	$2.7M+84.6%	$1.4M-26.2%	$2.0M-32.4%	$2.9M	N/A
Non-Current Liabilities	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0-100.0%	$332-100.0%	$5.7M+532.7%	$904K	$0	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$332-100.0%	$5.7M	N/A	N/A	N/A
Total Equity	$94.9M-21.1%	$120.3M-15.2%	$141.9M-0.4%	$142.5M-5.5%	$150.8M+453.7%	$27.2M+34.2%	$20.3M-9.1%	$22.3M-13.8%	$25.9M+310.3%	$6.3M-50.8%	$12.8M+6549.7%	$193K+107.8%	-$2.5M+14.3%	-$2.9M-151.7%	-$1.1M
Retained Earnings	-$382.4M-13.8%	-$336.1M-14.7%	-$293.1M-19.3%	-$245.6M-24.3%	-$197.6M-23.7%	-$159.7M-19.7%	-$133.4M-24.6%	-$107.1M-17.1%	-$91.5M-17.3%	-$78.0M-23.3%	-$63.3M-23.7%	-$51.2M	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A
Total Assets	$120.1M+17.3%	$128.8M+9.9%	$133.0M+7.2%	$103.8M-23.4%	$102.4M-27.6%	$117.1M-18.9%	$124.0M-16.2%	$135.6M-12.2%
Cash & Equivalents	$118.3M+17.0%	$127.4M+10.1%	$131.7M+9.1%	$102.6M-22.4%	$101.2M-27.1%	$115.8M-16.9%	$120.8M-16.0%	$132.2M-12.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$7.7M-33.0%	$7.1M-59.4%	$6.4M-51.5%	$8.9M-41.5%	$11.5M-2.4%	$17.4M+81.8%	$13.1M+5.1%	$15.3M+22.1%
Total Equity	$112.4M+23.6%	$121.7M+22.0%	$126.6M+14.2%	$94.9M-21.1%	$91.0M-29.9%	$99.8M-26.1%	$110.9M-18.2%	$120.3M-15.2%
Retained Earnings	-$385.6M-3.5%	-$393.5M-9.5%	-$388.1M-11.5%	-$382.4M-13.8%	-$372.6M-14.8%	-$359.4M-15.1%	-$348.2M-15.4%	-$336.1M-14.7%

Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.

AVXL Cash Flow Statement

AVXL quarterly cash flow statement

Metric	TTM	FY2510-K/A	FY2410-K/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$29.3M	-$39.0M-26.7%	-$30.8M-10.9%	-$27.8M-14.6%	-$24.2M+20.2%	-$30.4M-42.7%	-$21.3M-14.9%	-$18.5M-47.2%	-$12.6M-39.5%	-$9.0M+2.4%	-$9.2M-118.5%	-$4.2M-58.9%	-$2.7M-242.0%	-$778K	N/A	N/A
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1K+25.8%	$995+29.6%	$768+33.3%	$576-69.0%	$2K+12.1%	$2K
Stock-Based Compensation	N/A	$11.5M+22.4%	$9.4M-42.3%	$16.4M-10.9%	$18.4M+123.3%	$8.2M+68.8%	$4.9M-24.2%	$6.4M+16.6%	$5.5M+33.4%	$4.1M-18.3%	$5.1M+209.8%	$1.6M+156.1%	$638K-36.4%	$1.0M+231.7%	$302K-76.3%	$1.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3K	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$2.7M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$3K	$0	$0	$0
Financing Cash Flow	$46.5M	$9.4M-21.2%	$12.0M-59.6%	$29.7M+39.3%	$21.3M-86.1%	$153.2M+440.5%	$28.4M+59.4%	$17.8M+120.3%	$8.1M-70.4%	$27.3M+770.5%	$3.1M-74.4%	$12.3M+27.9%	$9.6M+762.0%	$1.1M	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A
Operating Cash Flow	-$9.1M+27.0%	-$4.4M+24.2%	-$7.2M+41.0%	-$8.6M-29.2%	-$12.5M-140.6%	-$5.9M+49.8%	-$12.1M-65.6%	-$6.7M-13.8%
Stock-Based Compensation	-$17.1M-495.1%	$314K-78.3%	$1.1M-46.1%	N/A	$4.3M+73.8%	$1.4M-45.4%	$2.1M-10.1%	N/A
Financing Cash Flow	$0+100.0%	$113K-86.7%	$36.3M+5030.4%	$10.0M+11155.1%	-$2.1M-147.1%	$852K-88.3%	$708K+1100.0%	$89K-95.7%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

AVXL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVXL quarterly financial ratios

Metric	FY2510-K/A	FY2410-K/A	FY2310-K/A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Return on Equity	-48.9%-13.1pp	-35.8%-2.3pp	-33.5%+0.2pp	-33.7%-8.5pp	-25.1%+71.4pp	-96.5%+33.1pp	-129.6%-52.3pp	-77.3%-25.3pp	-52.0%+181.6pp	-233.6%-139.1pp	-94.5%+5080.4pp	-5175.0%	N/A	N/A	N/A
Return on Assets	-44.7%-13.0pp	-31.7%-1.0pp	-30.8%+0.7pp	-31.4%-8.0pp	-23.5%+52.6pp	-76.1%+27.7pp	-103.8%-38.0pp	-65.8%-17.5pp	-48.4%+106.8pp	-155.1%-76.9pp	-78.3%+57.3pp	-135.6%	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	5.03-1.7x	6.71-1.0x	7.75+4.8x	2.96-2.9x	5.81+0.7x	5.10+4.9x	0.20+0.2x	0.00	N/A
Debt-to-Equity	0.090.0x	0.130.0x	0.090.0x	0.070.0x	0.07-0.2x	0.270.0x	0.25+0.1x	0.170.0x	0.14-0.4x	0.51+0.5x	0.00-29.7x	29.69	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A
Return on Equity	7.0%+21.5pp	-4.4%+6.8pp	-4.5%+6.4pp	N/A	-14.6%-5.2pp	-11.2%-3.4pp	-10.9%-4.6pp	N/A
Return on Assets	6.5%+19.4pp	-4.2%+5.4pp	-4.3%+5.5pp	N/A	-12.9%-4.3pp	-9.6%-2.3pp	-9.8%-3.9pp	N/A
Debt-to-Equity	0.07-0.1x	0.06-0.1x	0.05-0.1x	0.090.0x	0.130.0x	0.17+0.1x	0.120.0x	0.130.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Anavex Life Sciences AVXL	FY2025	N/A	-$46.4M	N/A	$242.9M	—
Zenas BioPharma, Inc. ZBIO	FY2025	$10.0M	-$377.7M	N/A	$2.0B	36/100
Praxis Precision Medicines, Inc. PRAX	FY2025	$0	-$303.0M	N/A	$9.3B	—
Geron Corp GERN	FY2025	N/A	-$83.5M	N/A	$867.3M	—
ArriVent BioPharma, Inc. AVBP	FY2025	N/A	-$166.3M	N/A	$1.4B	—
Tango Therapeutics, Inc. TNGX	FY2025	$62.4M	-$101.6M	N/A	$4.0B	65/100

Where Anavex Life Sciences Ranks

Frequently Asked Questions

Is Anavex Life Sciences profitable?

No, Anavex Life Sciences (AVXL) reported a net income of -$46.4M in fiscal year 2025.

What is Anavex Life Sciences's return on equity (ROE)?

Anavex Life Sciences (AVXL) has a return on equity of -48.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Anavex Life Sciences's operating cash flow?

Anavex Life Sciences (AVXL) recorded an outflow of $39.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Anavex Life Sciences's total assets?

Anavex Life Sciences (AVXL) had $103.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Anavex Life Sciences spend on research and development?

Anavex Life Sciences (AVXL) invested $37.6M in research and development during fiscal year 2025.

How many shares does Anavex Life Sciences have outstanding?

Anavex Life Sciences (AVXL) had 89M shares outstanding as of fiscal year 2025.

What is Anavex Life Sciences's debt-to-equity ratio?

Anavex Life Sciences (AVXL) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Anavex Life Sciences's return on assets (ROA)?

Anavex Life Sciences (AVXL) had a return on assets of -44.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Anavex Life Sciences's P/E ratio?

Anavex Life Sciences (AVXL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $242.9M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Anavex Life Sciences's price-to-sales ratio?

Anavex Life Sciences (AVXL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $242.9M as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Anavex Life Sciences's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Anavex Life Sciences (AVXL) held $102.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.0M over that year. Dividing the one by the other, the reported balance equals about 32 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Anavex Life Sciences's Piotroski F-Score?

Anavex Life Sciences (AVXL) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Anavex Life Sciences's earnings high quality?

Anavex Life Sciences (AVXL) reported a net loss of $46.4M while operations used $39.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Anavex Life Sciences cover its interest payments?

Anavex Life Sciences (AVXL) reported an operating loss of $51.4M against $4.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.